US Stock Market Move | Hims&Hers Health(HIM.US) resumed trading and continued to rise by over 12%, accumulating a total increase of 56% in two days.

On Tuesday, Hims & Hers Health (HIM.US) opened up more than 12%, with a two-day cumulative increase of 56%, now trading at $24.66. In terms of news, Novo Nordisk A/S Sponsored ADR Class B and Hims & Hers will collaborate on selling medications for obesity. Both companies have announced that Novo Nordisk A/S Sponsored ADR Class B has agreed to sell its flagship drugs Ozempic and Wegovy on the Hims platform, including the popular Wegovy oral tablets. Citigroup Inc. has given high praise to this collaboration in its latest research report, considering it a significant turning point in the development of Hims & Hers Health. Citigroup analysts point out that by introducing official medications, Hims & Hers has successfully overcome the compliance shadows and legal risks that have long plagued its business model. This shift from selling "compound generics" to "official partnerships" not only greatly enhances the sustainability of its business but also allows for deeper penetration into the lucrative weight loss medical market.